Madrigal Pharmaceuticals Announces Q2 2025 Financial Results Release and Upcoming Webcast

Madrigal Pharmaceuticals will release Q2 2025 financial results on August 5, 2025, before the US markets open. The company will host a live webcast to discuss its performance. The FDA-approved drug, Rezdiffra, for MASH treatment is a significant focus, with ongoing Phase 3 trials indicating continued investment. Investors will be keen to understand the financial implications of these trials during the webcast.

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) will release its second-quarter 2025 financial results on Wednesday, August 5, 2025, prior to the U.S. financial markets opening. The company will host a live webcast at 8 a.m. Eastern Time to discuss its performance and provide insights into its financial and operating results. The webcast will be available approximately two hours after the live event and can be accessed through the Investor Relations section of Madrigal Pharmaceuticals' website [1].

Madrigal Pharmaceuticals is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by the FDA for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c) [1].

The company recently secured a $500 million senior secured credit facility with funds managed by Blue Owl Capital (NYSE: OWL), a leading alternative asset manager. The non-dilutive financing consists of a $350 million initial term loan funded at closing, a $150 million delayed draw term loan facility (DDTL) available through December 2027, and an option for additional incremental facilities of up to $250 million [2]. The proceeds will primarily support Madrigal's pipeline expansion and refinance existing senior credit facilities. This financing will provide the company with the financial flexibility to advance the expansion of its pipeline and extend its leadership position in MASH.

Investors will be keen to understand the financial implications of these trials during the webcast. Madrigal's Chief Executive Officer, Bill Sibold, stated that the agreement with Blue Owl "meaningfully strengthens our capital position with non-dilutive funding to advance our MASH pipeline through smart, focused business development – a key element of our long-term growth strategy" [2].

The live webcast will provide valuable insights into Madrigal's financial health and strategic direction. Investors are encouraged to register at least 15 minutes prior to the scheduled webcast to ensure a timely connection.

References:
[1] https://www.nasdaq.com/press-release/madrigal-pharmaceuticals-release-second-quarter-2025-financial-results-and-host
[2] https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-secures-500-million-senior-secured